Discovery of First-in-Class hCA II/ROCK Dual Inhibitors with Both IOP-Lowering and Retinal Neuroprotective Activities for the Treatment of Glaucoma
Journal of Medicinal Chemistry · 20.11.2026
DOI: 10.1021/acs.jmedchem.6c02537 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 20.11.2026. Verfasst von Zhongyu Liu und 11 weiteren Autor:innen. Die Arbeit nennt 52 Literaturangaben. Gefördert von: Liaoning Revitalization Talents Program, Natural Science Foundation of Liaoning Province, Department of Education of Liaoning Province.
Abstract (Originalsprache)
Glaucoma is the leading cause of irreversible blindness worldwide. Current first-line therapies frequently yield suboptimal intraocular pressure (IOP) control. Furthermore, many patients develop progressive visual field loss despite adequate pressure management. To address this gap, we developed a class of first-in-class dual-target inhibitors against carbonic anhydrase II (CA II) and Rho-associated coiled-coil-containing protein kinase (ROCK). Among them, A3 showed 6250-fold higher hCA II inhibitory potency than the initial fragment with favorable selectivity and 1.2-/1.7-fold higher ROCK1/2 inhibitory activity than fasudil. In vivo, A3 produced potent and sustained IOP reduction across multiple models. Notably, in the DBA/2J spontaneous glaucoma model, it potently lowered IOP and preserved retinal structural integrity. Meanwhile, A3 attenuated retinal ganglion cell apoptosis via its antioxidant and anti-inflammatory effects, thereby conferring optic neuroprotection with favorable systemic safety. Overall, A3 overcomes key limitations of current antiglaucoma drugs and represents a promising candidate for combined IOP-lowering and optic neuroprotective therapy.
Förderung
- Liaoning Revitalization Talents Program
- Natural Science Foundation of Liaoning Province
- Department of Education of Liaoning Province
- National Natural Science Foundation of China
Zitieren
APA
Liu, Z., Li, H., Zheng, Y., Qin, L., Wang, M., Wang, X., Guo, M., Wang, Y., Mou, Y., Peng, C., Hou, Z., & Guo, C. (2026). Discovery of First-in-Class hCA II/ROCK Dual Inhibitors with Both IOP-Lowering and Retinal Neuroprotective Activities for the Treatment of Glaucoma. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c02537
Vancouver
Liu Z, Li H, Zheng Y, Qin L, Wang M, Wang X, et al. Discovery of First-in-Class hCA II/ROCK Dual Inhibitors with Both IOP-Lowering and Retinal Neuroprotective Activities for the Treatment of Glaucoma. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c02537
BibTeX
@article{Liu2026,
author = {Liu, Zhongyu and Li, Haoying and Zheng, Yu and Qin, Lixia and Wang, Manru and Wang, Xin and Guo, Mengbi and Wang, Yitong and Mou, Yanhua and Peng, Cheng and Hou, Zhuang and Guo, Chun},
title = {Discovery of First-in-Class hCA II/ROCK Dual Inhibitors with Both IOP-Lowering and Retinal Neuroprotective Activities for the Treatment of Glaucoma},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.6c02537}
}
EUVIMED